Contemporary approaches to correction of cognitive impairment in endogenous depression
https://doi.org/10.31363/2313-7053-2020-4-82-93
Abstract
Cognitive dysfunction is one of the basic symptoms of endogenous depression, gaining much of the researchers’ interest lately. It is observed at the initial stage, at the peak intensity of depressive symptoms and even after their reduction, which leads to the persistence of residual depressive state. Cognitive impairment during the depressive episode can be detected by objective methods (clinical and neuropsychological), and their subjective importance is being revealed by standardized questionnaires. Depressed patients show lower results in executive functions, working memory, reaction speed, verbal learning, immediate and delayed recall subtests of neuropsychological batteries. There are few pharmacological agents (mostly antidepressants) with well-proven procognitive activity in depression. Besides, some new pharmacological and non-pharmacological approaches for treatment of cognitive impairment in depression have appeared lately and are described in literature as promising.
About the Authors
I. V. Oleichik
Mental Health Research Center
Russian Federation
Russian Federation
T. I. Shishkovskaia
Mental Health Research Center
Russian Federation
Russian Federation
P. A. Baranov
Mental Health Research Center
Russian Federation
Russian Federation
References
1. Беккер Р.А., Быков Ю.В.Bekker R.A., Bykov YuV. Kognitivnye narusheniya pri depressiyakh: klinicheskoe znachenie i sovremennye vozmozhnosti terapii. Psikhiatriya i psikhofarmakoterapiya. 2015;17(4):40-45.
2. Konoreva A.E., Mosolov S.N. Kognitivnye narusheniya pri bipolyarnom affektivnom rasstroistve. Sovremennaya terapiya psikhicheskikh rasstroistv. 2017;4:11-18.
3. Medvedev V.Eh. Sigma-retseptory: rol’ v lechenii affektivnykh rasstroistv. Nevrologiya, neiropsikhiatriya, psikhosomatika. 2012:2.
4. Miroshnichenko I.I. Sposoby povysheniya i vosstanovleniya kognitivnykh funktsii. Psikhiatriya. 2020;18(1):71-78.
5. Neznanov N.G., Mazo G.Eh., Rukavishnikov G.V. Vliyanie antidepressantov na kognitivnye funktsii patsientov s depressivnym rasstroistvom. Obozrenie psikhiatrii i meditsinskoi psikhologii imeni VM Bekhtereva. 2015;3:75-82.
6. Petrova, N.N., Yanchenko, M.A. Depressiya i kognitivnye narusheniya. Nevrёдорова А.И., Ахапкин Р.В., Файзуллоев А.З. Предикторы терапевтической динамики когнитивных нарушений при депрессивных расстройствах непсихотического уровня. Российский психиатрический журнал. 2019;1. Fedorova A.I., Akhapkin R.V., Faizulloev A.Z. Prediktory terapevticheskoi dinamiki kognitivnykh narushenii pri depressivnykh rasstroistvakh nepsik-hoticheskogo urovnya. Rossiiskii psikhiatricheskii zhurnal. 2019:1.
7. Shagiakhmetov F.Sh., Anokhin P.K., Shamakina I.Yu. Vortioksetin: mekhanizmy mul’timodal’nosti i klinicheskaya ehffektivnost’. Sotsial’naya i klinicheskaya psikhiatriya. 2016:26(4).
8. Shmukler A.B. Znachenie kognitivnykh narushenii dlya otsenki patogeneza, klinicheskoi kartiny i lecheniya depressii. Sotsial’naya i klinicheskaya psikhiatriya. 2016:26(4).
9. Yanushko M.G., Shamanina M.V., Aristova T.A., Richard K., Ivanov, M.V., & Tolmacheva, M. Standartizatsiya shkaly «Kratkaya otsenka kognitivnykh funktsii u patsientov s affektivnymi rasstroistvam»(BAC-A) na osnove normativnykh dannykh rossiiskoi populyatsii. Rossiiskii psikhiatricheskii zhurnal. 2015:2.
10. Anderson R.J., Freedland K.E., Clouse R.E., Lustman, P.J. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes care. 2001;24(6):1069-1078. Doi:10.2337/diacare.24.6.1069
11. Baptiste D.C., Hartwick A.T., Jollimore C.A., Baldridge W.H., Seigel G.M., Kelly M.E. An investigation of the neuroprotective effects of tetracycline derivatives in experimental models of retinal cell death. Molecular pharmacology. 2004;66(5):1113- 1122. Doi:10.1124/mol.104.001081
12. Baune B.T., Brignone M., Larsen K.G. A network meta-analysis comparing effects of various antidepressant classes on the digit symbol substitution test (DSST) as a measure of cognitive dysfunction in patients with major depressive disorder. International Journal of Neuropsychopharmacology. 2018;21(2):97-107. doi:10.1093/ijnp/pyx070
13. Blier P., El Mansari M. Serotonin and beyond: therapeutics for major depression. Philosophical Transactions of the Royal Society B: Biological Sciences. 2013;368:1615, 20120536. doi:10.1098/rstb.2012.0536
14. Bortolato B., Miskowiak K.W., Köhler C.A., Maes M., Fernandes B.S., Berk M., Carvalho A.F. Cognitive remission: a novel objective for the treatment of major depression?. BMC medicine. 2016;14(1):9. Doi:10.1186/s12916-016-0560-3
15. Braszko J.J., Karwowska-Polecka W., Halicka D., Gard P.R. Captopril and enalapril improve cognition and depressed mood in hypertensive patients. Journal of basic and clinical physiology and pharmacology. 2003;14(4):323-344. Doi:10.1515/JBCPP.2003.14.4.323
16. Cha D.S., Best M.W., Bowie C.R., Gallaugher L.A., Woldeyohannes H.O., Soczynska J.K., Lui J. P. A randomized, double-blind, placebo-controlled, crossover trial evaluating the effect of intranasal insulin on cognition and mood in individuals with treatment-resistant major depressive disorder. Journal of Affective Disorders. 2017;210:57-65. doi:10.1016/j.jad.2016.12.006
17. Crowe S.F., Stranks E.K. The residual medium and long-term cognitive effects of benzodiazepine use: an updated meta-analysis. Archives of Clinical Neuropsychology. 2018;33(7):901-911. doi:10.1093/arclin/acx120
18. Daskalakis Z.J., Dimitrova J., McClintock S.M., Sun Y., Voineskos D., Rajji T.K., Downar J. Magnetic seizure therapy (MST) for major depressive disorder. Neuropsychopharmacology. 2020;45(2):276- 282. doi:10.1038/s41386-019-0515-4
19. Dean O.M., Kanchanatawan B., Ashton M., Mohebbi M., Ng C.H., Maes M., McKenzie H. Adjunctive minocycline treatment for major depressive disorder: a proof of concept trial. Australian & New Zealand Journal of Psychiatry. 2017;51(8):829-840. doi:10.1177/0004867417709357
20. Dean O.M., Data-Franco J., Giorlando F., Berk M. (2012). Minocycline. CNS drugs, 26(5), 391-401. doi:10.2165/11632000-000000000-00000
21. Dias V.V., Balanzá‐Martinez V., Soeiro‐de‐Souza M.G., Moreno R.A., Figueira M.L., Machado‐Vieira R., Vieta E. (2012). Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview. Acta Psychiatrica Scandinavica, 126(5), 315-331. doi:10.1111/j.1600-0447.2012.01910.x
22. Elgamal S., MacQueen G. (2008). Galantamine as an adjunctive treatment in major depression. Journal of clinical psychopharmacology, 28(3), 357-359. doi:10.1097/JCP.0b013e318172756c
23. Fourrier C., Sampson E., Mills N.T., Baune B.T. (2018). Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo. Trials, 19(1), 447. doi:10.1186/s13063-018-2829-7
24. Fregni F., Boggio P.S., Nitsche M.A., Rigonatti S.P., Pascual‐Leone A. (2006). Cognitive effects of repeated sessions of transcranial direct current stimulation in patients with depression. Depression and anxiety, 23(8), 482-484. doi:10.1002/da.20201
25. Furey M.L., Drevets W.C. (2006). Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Archives of general psychiatry, 63(10), 1121-1129. doi:10.1001/archpsyc.63.10.1121
26. Herrera-Guzmán I., Gudayol-Ferré E., Herrera-Guzmán D., Guàrdia-Olmos J., Hinojosa-Calvo, E. Herrera-Abarca J. E. (2009). Effects of selective serotonin reuptake and dual serotonergic–noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder. Journal of psychiatric research, 43(9), 855-863. doi:10.1016/j.jpsychires.2008.10.015
27. Husain M.I., Chaudhry I.B., Husain N., Khoso A.B., Rahman R.R., Hamirani M.M., Young A.H. (2017). Minocycline as an adjunct for treatment-resistant depressive symptoms: a pilot randomised placebo-controlled trial. Journal of Psychopharmacology, 31(9), 1166-1175. doi:10.1177/0269881117724352
28. Kampf-Sherf O., Zlotogorski Z., Gilboa A., Speedie L., Lereya J., Rosca P., Shavit Y. (2004). Neuropsychological functioning in major depression and responsiveness to selective serotonin reuptake inhibitors antidepressants. Journal of affective disorders, 82(3), 453-459. doi:10.1016/j.jad.2004.02.006
29. Kaser M., Deakin J.B., Michael A., Zapata C., Bansal R., Ryan D., Sahakian B.J. (2017). Modafinil improves episodic memory and working memory cognition in patients with remitted depression: a double-blind, randomized, placebo-controlled study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2(2), 115-122. doi:10.1016/j.bpsc.2016.11.009
30. Katona C.L., Katona C.P. (2014). New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. Neuropsychiatric disease and treatment, 10, 349. doi:10.2147/NDT.S39544
31. Keefe R.S., McClintock S.M., Roth R.M., Doraiswamy P.M., Tiger S., Madhoo M. (2014). Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review. The Journal of clinical psychiatry, 75(8), 864-876. doi:10.4088/JCP.13r08609
32. Keefe R.S., Sweeney J.A., Gu H., Hamer R.M., Perkins D.O., McEvoy J.P., Lieberman J.A. (2007). Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. American Journal of Psychiatry, 164(7), 1061-1071. doi:10.1176/ajp.2007.164.7.1061
33. Khan A., Ginsberg L.D., Asnis G.M., Goodwin F.K., Davis K.H., Krishnan A.A., Adams B.E. (2004). Effect of lamotrigine on cognitive complaints in patients with bipolar I disorder. The Journal of clinical psychiatry, 65(11), 1483-1490. doi:10.4088/JCP.v65n1107
34. Kishi T., Matsunaga S., Iwata N. (2017). A meta-analysis of memantine for depression. Journal of Alzheimer’s Disease, 57(1), 113-121. doi:10.3233/JAD-161251
35. Knight M.J., Mills N.T., Baune B.T. (2019). Contemporary methods of improving cognitive dysfunction in clinical depression. Expert review of neurotherapeutics, 19(5), 431-443. doi:10.1080/14737175.2019.1610395
36. Listunova L., Roth C., Bartolovic M., Kienzle J., Bach C., Weisbrod M., Roesch-Ely D. (2018). Cognitive impairment along the course of depression: Non-pharmacological treatment options. Psychopathology, 51(5), 295-305. doi:10.1159/000492620
37. Lundbeck. FDA Updates TrintellixR (vortioxetine) Label to Include Data Showing Improvement in Processing Speed, an Important Aspect of Cognitive Function in acute Major Depressive Disorder (MDD). (2018). Дата обновления 02.05.2018, дата обращения 30.07.2020 Доступно на: https://globenewswire.com/newsre-lease/2018/05/02/1495434/0/en/FDA-updates-Trin-tellix-vortioxetine-label-to-include-data-showing-improvement-in-processing-speed-an-importantaspect-of-cognitivefunction-in-acute-Major-Depres-sive-Disorder-MDD.html
38. Madhoo M., Keefe R.S., Roth R.M., Sambunaris A., Wu J., Trivedi M.H., Lasser R. (2014). Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder. Neuropsychopharmacology, 39(6), 1388-1398. doi:10.1038/npp.2013.334
39. Mahableshwarkar A.R., Zajecka J., Jacobson W., Chen Y., Keefe R.S. (2015). A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology, 40(8), 2025-2037. doi:10.1038/npp.2015.52
40. Masand P.S. (2003). Tolerability and adherence issues in antidepressant therapy. Clinical therapeutics, 25(8), 2289-2304.
41. McFarland A.J., Anoopkumar-Dukie S., Arora D.S., Grant G.D., McDermott C.M., Perkins A.V., Davey A.K. (2014). Molecular mechanisms underlying the effects of statins in the central nervous system. International journal of molecular sciences, 15(11), 20607-20637. doi:10.3390/ijms151120607
42. McIntyre R.S., Cha D.S., Soczynska J.K., Woldeyohannes H.O., Gallaugher L.A., Kudlow P., Baskaran A. (2013). Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depression and anxiety, 30(6), 515-527. doi:10.1002/da.22063
43. Millan M.J., Agid Y., Brüne M., Bullmore E.T., Carter C.S., Clayton N.S., Dubois B. (2012). Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nature reviews Drug discovery, 11(2), 141-168. doi:10.1038/nrd3628
44. Misiak B., Beszłej J.A., Kotowicz K., Szewczuk-Bogusławska M., Samochowiec J., Kucharska-Mazur J., Frydecka D. (2018). Cytokine alterations and cognitive impairment in major depressive disorder: From putative mechanisms to novel treatment targets. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 80, 177-188. doi:10.1016/j.pnpbp.2017.04.021
45. Miskowiak K., Inkster B., O’Sullivan U., Selvaraj S., Goodwin G.M., Harmer C.J. (2008). Differential effects of erythropoietin on neural and cognitive measures of executive function 3 and 7 days post-administration. Experimental brain research, 184(3), 313-321.
46. Miskowiak K.W., Vinberg M., Christensen E.M., Bukh J.D., Harmer C.J., Ehrenreich H., Kessing L.V. (2014). Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial. Neuropsychopharmacology, 39(6), 1399-1408. doi:10.1038/npp.2013.335
47. Miskowiak K.W., Ott C.V., Petersen J.Z., Kessing L.V. (2016). Systematic review of randomized controlled trials of candidate treatments for cognitive impairment in depression and methodological challenges in the field. European Neuropsychopharmacology, 26(12), 1845-1867. doi:10.1016/j.euroneuro.2016.09.641
48. Mohn C., Rund B.R. (2019). Neurognitive function and symptom remission 2 years after ECT in major depressive disorders. Journal of Affective Disorders, 246, 368-375. doi:10.1016/j.jad.2018.12.083
49. Mospan C.M. Are statins protective or harmful to cognitive function? Journal of the American Academy of Pas. 2016;29(1):11-12.
50. Nierenberg A.A., Loft H., Olsen C.K. Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine. Journal of Affective Disorders. 2019;250:35-42.
51. Ortinski P., Meador K.J. Cognitive side effects of antiepileptic drugs. Epilepsy & Behavior. 2004;5:60-65. doi:10.1016/j.yebeh.2003.11.008
52. Ott C.V., Vinberg M., Kessing L.V., Miskowiak K.W. The effect of erythropoietin on cognition in affective disorders–Associations with baseline deficits and change in subjective cognitive complaints. European Neuropsychopharmacology. 2016;26(8):1264-1273. doi:10.1016/j.euroneuro.2016.05.009
53. Pehrson A.L., Hillhouse T.M., Haddjeri N., Rovera R., Porter J.H., Mørk A., Sanchez C. Task- and Treatment Length–Dependent Effects of Vortioxetine on Scopolamine-Induced Cognitive Dysfunction and Hippocampal Extracellular Acetylcholine in Rats. Journal of Pharmacology and Experimental Therapeutics. 2016;358(3):472-482. doi:10.1124/jpet.116.233924
54. Pelton G.H., Harper O.L., Roose S.P., Marder K., D’Antonio K., Devanand D.P. Combined treatment with memantine/es‐citalopram for older depressed patients with cognitive impairment: a pilot study. International Journal of Geriatric Psychiatry. 2016;31(6):648-655. doi:10.1002/gps.4375
55. Prado C.E., Watt S., Crowe S.F. A meta-analysis of the effects of antidepressants on cognitive functioning in depressed and non-depressed samples. Neuropsychology review. 2018;28(1):32-72. doi:10.1007/s11065-018-9369-5
56. Pu S., Setoyama S., Noda T. Association between cognitive deficits and suicidal ideation in patients with major depressive disorder. Scientific reports. 2017;7(1):1-6. doi:10.1038/s41598-017-12142-8
57. Rigal A., Mouchabac S., Peretti C.S. Interest of scopolamine as a treatment of major depressive disorder. L’Encephale. 2016;42(6):568.
58. Roca M., López-Navarro E., Monzón S., Vives M., García-Toro M., García-Campayo J., Gili M. Cognitive impairment in remitted and non-remitted depressive patients: A follow-up comparison between first and recurrent episodes. European Neuropsychopharmacology. 2015;25(11):1991-1998. doi:10.1016/j.euroneuro.2015.07.020
59. Roiser J.P., Sahakian B.J. Hot and cold cognition in depression. CNS spectrums. 2013;18(3):139-149. doi:10.1017/S1092852913000072
60. Rosenblat J.D., Kakar R., McIntyre R.S. (2016). The cognitive effects of antidepressants in major depressive disorder: a systematic review and meta-analysis of randomized clinical trials. International Journal of Neuropsychopharmacology, 19(2). doi:10.1093/ijnp/pyv082
61. Russo M., Mahon K., Burdick K.E. (2015). Measuring cognitive function in MDD: emerging assessment tools. Depression and anxiety, 32(4), 262-269.
62. Sanchez C., Asin K.E., Artigas F. (2015). Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacology & therapeutics, 145, 43-57. doi:10.1016/j.pharmthera.2014.07.001
63. Sarter M., Lustig C., Taylor S.F. (2012). Cholinergic contributions to the cognitive symptoms of schizophrenia and the viability of cholinergic treatments. Neuropharmacology, 62(3), 1544-1553. doi:10.1016/j.neuropharm.2010.12.001
64. Scuteri A., Spazzafumo L., Cipriani L., Gianni W., Corsonello A., Cravello L., Sebastiani M. (2011). Depression, hypertension, and comorbidity: disentangling their specific effect on disability and cognitive impairment in older subjects. Archives of gerontology and geriatrics, 52(3), 253-257. doi:10.1016/j.archger.2010.04.002
65. Semkovska M., Quinlivan L., O’Grady T., Johnson R., Collins A., O’Connor J., Gload T. (2019). Cognitive function following a major depressive episode: a systematic review and meta-analysis. The Lancet Psychiatry, 6(10), 851-861. doi:10.1016/S2215-0366(19)30291-3
66. Semkovska M., Ahern E. (2017). Online neurocognitive remediation therapy to improve cognition in community-living individuals with a history of depression: A pilot study. Internet Interventions, 9, 7-14. doi:10.1016/j.invent.2017.04.003
67. Shemesh E., Rudich A., Harman-Boehm I., Cuk- ierman-Yaffe T. (2012). Effect of intranasal insulin on cognitive function: a systematic review. The Journal of Clinical Endocrinology & Metabolism, 97(2), 366-376. doi:10.1210/jc.2011-1802
68. Silberner J. (2019). Ketamine based drug should be available for treatment resistant depression, says FDA panel.
69. Soh J.F., Almadani A., Beaulieu S., Rajji T., Mulsant B. H., Su C.L., Schaffer A. (2020). The effect of atorvastatin on cognition and mood in bipola disorder and unipolar depression patients: A secondary analysis of a randomized controlled trial. Journal of affective disorders, 262, 149-154.
70. Spielman L.J., Little J.P., Klegeris A. (2014). Inflammation and insulin/IGF-1 resistance as the possible link between obesity and neurodegeneration. Journal of neuroimmunology, 273(1-2), 8-21. doi:10.1016/j.jneuroim.2014.06.004
71. Stranks E.K., Crowe S.F. (2014). The acute cognitive effects of zopiclone, zolpidem, zaleplon, and eszopiclone: a systematic review and meta-analysis. Journal of clinical and experimental neuropsychology, 36(7), 691-700. doi:10.1080/13803395.2014.928268
72. Strzelecki D., Tabaszewska A., Barszcz Z., Józefowicz O., Kropiwnicki P., Rabe-Jabłońska J. (2013). A 10-week memantine treatment in bipolar depression: a case report. Focus on depressive symptomatology, cognitive parameters and quality of life. Psychiatry Investigation, 10(4), 421. doi:10.4306/pi.2013.10.4.421
73. Timm C., Rachota-Ubl B., Beddig T., Zamoscik V.E., Ebner-Priemer U., Reinhard I., Kuehner C. (2018). Mindfulness-based attention training improves cognitive and affective processes in daily life in remitted patients with recurrent depression: a randomized controlled trial. Psychotherapy and psychosomatics, 87(3). doi:10.1159/000488862
74. Veselinović T., Scharpenberg M., Heinze M., Cordes J., Mühlbauer B., Juckel G., Bleich S. (2019). Disparate effects of first and second generation anti-psychotics on cognition in schizophrenia–Findings from the randomized NeSSy trial. European Neuropsychopharmacology, 29(6), 720-739. doi:10.1016/j.euroneuro.2019.03.014
75. Wang J., Vila-Rodriguez F., Ge R., Gao S., Gregory E., Jiang W., Wang G. (2020). Accelerated magnetic seizure therapy (aMST) for treatment of major depressive disorder: A pilot study. Journal of Affective Disorders, 264, 215-220. doi:10.1016/j.jad.2019.12.022
76. Wingo A.P., Wingo T.S., Harvey P.D., Baldessarini R.J. (2009). Effects of lithium on cognitive performance: a meta-analysis. In Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. Centre for Reviews and Dissemination (UK). doi:10.4088/JCP.08r04972
77. Wolkenstein L., Plewnia C. (2013). Amelioration of cognitive control in depression by transcranial direct current stimulation. Biological psychiatry, 73(7), 646-651. doi:10.1016/j.biopsych.2012.10.010
78. Xiao L., Feng L., Zhu X.Q., Feng Y., Wu W.Y., Ungvari G.S., Wang G. (2018). Comparison of residual depressive symptoms and functional impairment between fully and partially remitted patients with major depressive disorder: a multicenter study. Psychiatry research, 261, 547-553. doi:10.1016/j.psychres.2018.01.020
79. Yatham M.S., Yatham K.S., Ravindran A.V., Sullivan F. Do statins have an effect on depressive symptoms? A systematic review and meta-analysis. Journal of affective disorders. 2018;257:55-63. doi:10.1016/j.jad.2019.07.002
80. Zavodnick A.D., Ali R. Lamotrigine in the treatment of unipolar depression with and without comorbidities: a literature review. Psychiatric Quarterly. 2012;83(3):371-383. doi:10.1007/s11126-012-9208-4
81. Zheng W., Zhu X.M., Zhang Q.E., Cheng G., Cai D.B., He J., Xiang Y.T. Adjunctive minocycline for major mental disorders: a systematic review. Journal of Psychopharmacology. 2019;33(10):1215-1226. doi:10.1177/0269881119858286
82. Zuckerman H., Pan Z., Park C., Brietzke E., Musial N., Shariq A.S., McIntyre R.S. Recognition and treatment of cognitive dysfunction in major depressive disorder. Frontiers in Psychiatry. 2018;9:655. doi:10.3389/fpsyt.2018.00655
Review
For citations:
Oleichik I.V., Shishkovskaia T.I., Baranov P.A. Contemporary approaches to correction of cognitive impairment in endogenous depression. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY. 2020;(4):82-93. (In Russ.) https://doi.org/10.31363/2313-7053-2020-4-82-93
Views:
1217
Email this article 